KFDA approves Leukemia drug, Gleevec.

Published: 2001-06-25 06:58:00

Updated: 2001-06-25 06:58:00

The KFDA announced on June 20 that Novartis' Gleevec (imtainib mesylate), a leukemia drug, was approved to sell in Korea on June 14 as an orphan drug with precondition of its clinical phase III study for the treatment of chronic myelogenous leukemia.

The Central Pharmaceutical Affairs Review C...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK